Advertisement
Screener

FOXO TECHNOLOGIES INC. (FOXO) Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest

2.5 / 5 stars · 14/28 Roast Me

FOXO TECHNOLOGIES INC. Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest

FOXO TECHNOLOGIES INC. (FOXO) reported Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest of -$132.25 thousand for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-12.

Discontinued › Shareholders' Equity

us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest · last filed 2022-08-12

  • FOXO TECHNOLOGIES INC. net income (loss), including portion attributable to nonredeemable noncontrolling interest for the quarter ending 2022-06-30 was -$132.25K, a 107.12% decline year-over-year.
  • FOXO TECHNOLOGIES INC. net income (loss), including portion attributable to nonredeemable noncontrolling interest for the quarter ending 2022-03-31 was -$376.97K, a 107.54% decline year-over-year.
  • FOXO TECHNOLOGIES INC. net income (loss), including portion attributable to nonredeemable noncontrolling interest for the quarter ending 2021-12-31 was $1.14M.
  • FOXO TECHNOLOGIES INC. net income (loss), including portion attributable to nonredeemable noncontrolling interest for the quarter ending 2021-09-30 was $367.04K.
  • FOXO TECHNOLOGIES INC. net income (loss), including portion attributable to nonredeemable noncontrolling interest for fiscal 2021 was $4.65M.
Period endNet Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest 3 monthNet Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest 6 monthNet Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest 8 monthNet Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest 9 monthNet Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest 12 month
2022-06-30-$132.25K
10-Q · filed 2022-08-12
-$509.23K
10-Q · filed 2022-08-12
$631.70K
derived: sum of 3 quarters · filed 2022-08-12
$998.74K
derived: sum of 4 quarters · filed 2022-08-12
2022-03-31-$376.97K
10-Q · filed 2022-05-16
$763.96K
derived: sum of 2 quarters · filed 2022-05-16
$1.13M
derived: sum of 3 quarters · filed 2022-05-16
$2.99M
derived: sum of 4 quarters · filed 2022-08-12
2021-12-31$1.14M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07
$1.51M
derived: sum of 2 quarters · filed 2022-03-07
$3.37M
derived: sum of 3 quarters · filed 2022-08-12
$4.65M
10-K · filed 2022-03-07
2021-09-30$367.04K
10-Q · filed 2021-11-15
$2.22M
derived: sum of 2 quarters · filed 2022-08-12
$3.51M
10-Q · filed 2021-11-15
2021-06-30$1.86M
10-Q · filed 2022-08-12
$3.14M
10-Q · filed 2022-08-12
2021-03-31$5.00M
10-Q · filed 2022-05-16
2020-12-31-$1.78M
10-K · filed 2022-03-07

Similar stocks

Stock NameCountryMarket CapPE Ratio
iSpecimen Inc. (ISPC)United States$0.003B
OneMedNet Corp (ONMD)$0.042B
bioAffinity Technologies, Inc. (BIAF)United States$0.063B
MAXCYTE, INC. (MXCT)United States$0.124B-3.68
NRC HEALTH (NRC)United States$0.450B42.50
OmniAb, Inc. (OABI)United States$0.698B-8.05
Absci Corp (ABSI)United States$1.775B-14.92
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)United States$14.060B-43.97
Medpace Holdings, Inc. (MEDP)United States$17.316B30.09
INCYTE CORP (INCY)United States$24.855B13.14